Personalized Chemotherapy Based on O6-methylguanine-DNA methyltransferase (MGMT) Expression Pattern for Glioma Patients
Jun-ping Zhang,Da-nian Wei,Gang Li,Yong-gao Mu,Xiang-heng Zhang,Ke Sai,Zhong-ping Chen
2009-01-01
Abstract:BACKGROUND & OBJECTIVE:Expression of O6-methylguanine-DNA methyltransferase (MGMT) has been related to drug resistance of glioma patients. This article is to analyze whether personalized chemotherapy based on MGMT expression could be benefit to patients with MGMT positive gliomas. METHODS:There were 57 malignant glioma patients (anaplastic oligodendroglioma, AO 3 cases, anaplastic astrocytoma, AA 36 cases, glioblastoma multiforme, GBM 18 cases) received chemotherapy in Cancer Center of Sun Yat-sen University, based on MGMT expression, and response as well as survival time were evaluated. Thirty-five patients withMGMT positive tumors received chemotherapy regimens, which consisted of no-alklating agent regimen or cisplatin plus TMZ regimen, or combination of TMZ or nitrosoureas with no-alklating agent (teniposide (VM-26), cisplatin (DDP), carboplatin (CBP), isophosphamide (IFO), etoposide (VP16)). While 22 patients with MGMT negative tumors, there was no restriction on chemotherapy regimen. That was eigther nitrourea or TMZ had been used in the regimen, and the most commonly used regimen were PCV;TMZ +VM26; MeCCNU +VM26. RESULT: Although objective response (OR) and response rate (RR) in the patients with MGMT negative tumors were higher than that in the patients with MGMT positive tumors, but there was no statistical significance between those two groups (P >0.05). By following up 0.7-53.4 months (mean 11.7 months), progressive-free survival (PFS) in MGMT negative and positive patients were 8.5 months(95% CI 4.8-19.3) and 6.7 months(95% CI 3.7-9.3), and overall survival(OS) were 20.3 months (95% CI 14.3-) and 16.1 months (95% CI 11.1-26.2, respectively. (P>0.05). CONCLUSIONS:Our results indicated that personized chemotherapy for glioma patients based on MGMT expression can obtain satisfactory results especially for patients with MGMT positive gliomas.